In addition, the proportion of intrinsic subtypes was comparable between control and treated groups with the controls slightly enriched with HER2-E (54% vs 41·4%) and reduced Luminal A tumours (8·0% vs 21·1%), not statistically significantly different (p>0·05), Within the treated subgroup, 31% achieved GR, 22·5% were IRs and 46·5% PRs, while 52·0% had Ki672wk High and 48·0% Low, respectively. This evidence concerns the gene ERBB2 and neoplasm.